Deprivation and prognosis in patients with Pulmonary Arterial Hypertension: missing the effect of deprivation on a rare disease?

Eleni Sofianopoulou, Colin Church, Gerry Coghlan, Luke Howard, Martin Johnson, David G. Kiely, Allan Lawrie, James Lordan, Martin R. Wilkins, Stephen J. Wort, Nicholas W. Morrell, Mark R. Toshner


This manuscript has recently been accepted for publication in the *European Respiratory Journal*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.
Deprivation and prognosis in patients with Pulmonary Arterial Hypertension: missing the effect of deprivation on a rare disease?

Eléni Sofianopoulou1, Colin Church2, Gerry Coghlan3, Luke Howard4, Martin Johnson2, David G. Kiely5, Allan Lawrie6, James Lordan7, Martin R. Wilkins4, Stephen J. Wort8,9, Nicholas W. Morrell8,10, Mark R. Toshner9
1. Department of Public Health and Primary Care, Cardiovascular Epidemiology Unit, University of Cambridge, Cambridge, CB1 8RN, United Kingdom; 2. Golden Jubilee National Hospital, Glasgow, G81 4DY, United Kingdom; 3. Royal Free Hospital, London, NW3 2QG, United Kingdom; 4. Imperial College London, London, SW7 2AZ, United Kingdom; 5. Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, S10 2JF, United Kingdom; 6. Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, S10 2RX, United Kingdom; 7. University of Newcastle, Newcastle, NE1 7RU, United Kingdom; 8. Royal Brompton Hospital, London, SW3 6NP, United Kingdom; 9. Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, United Kingdom; 10. NIHR BioResource - Rare Diseases, Cambridge, CB2 0PT, United Kingdom

In this journal, Pellino et al presented survival analysis to assess how deprivation affects prognosis in patients with pulmonary arterial hypertension (PAH)5. Their conclusions were that social deprivation is not a significant referral barrier or prognostic factor for idiopathic (I)PAH or heritable (H)PAH in Scotland. This may appear surprising given the wider context of literature describing outcomes stratified by social deprivation. The authors were thorough on using both the address at time of diagnosis and at time of censoring to assign deprivation scores and compare the two, finding no significant differences between the two approaches. They also compared deprivation assigned to PAH cases to expected deprivation based on Scottish citizenry as a whole and found that PAH patients are more socially deprived than expected. Finally, they used the same survival univariate analysis adjusting for age and sex to assess how several clinical variables are associated with prognosis.

The ongoing National_Cohort_Study_of_Idiopathic_and_Heritable_PAH collects data from all of the UK and offers an opportunity to test the relationship between deprivation and outcomes in PAH in a second population that is geographically distinct but in many other ways highly analogous to the Pellino et al work. The study collects data from a contemporaneous cohort in all of the specialist PAH centres in the UK. Therefore, we were able to assess mortality in relation to deprivation in 270 PAH patients living in England and Wales, residing in the same addresses since diagnosis. Our patients were recruited in the UK PAH cohort from January 1st 2014 and followed-up until February 28th 2019. 36 (13%) participants died and five (2%) were transplanted, resulting in 1-, 3- and 5-year transplant-free survival estimates of 96%, 86% and 73% for incident patients (N=146) and 100%, 100% and 89% for prevalent patients (N=124), respectively. Pellino et al captured deprivation using the Scottish Index of Multiple Deprivation (IMD), which is a composite index comprising of sub-indices (e.g. income, education, employment, health, access to services, crime). In the UK, IMD is not comparable between England, Scotland and Wales, so for our UK cohort we accessed an adjusted IMD index for use across the UK7, that consists of the three main domains of IMD: income, employment and educational deprivation. In addition to the area level deprivation captured via the UK-IMD, the primary survival model was adjusted for age at diagnosis and sex, to be in line with the adjustment used by Pellino et al, fitting Cox proportional hazards regression models. Cox proportional hazards regression models and survival curves were fitted allowing for left truncation arising from the interval between diagnosis of prevalent cases and enrolment. Prevalent patients were only included in the risk set from the time of study entry and were excluded if they entered the study >10 years after diagnosis. We stratified the analysis by centre, due to the multicentre design of our study. In the extended model, we further adjusted for smoking, prevalent/incident status and risk profiles
(low/intermediate/high) at the time of diagnosis, calculated using the abbreviated 2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) risk stratification strategy\textsuperscript{3}. According to data availability, the risk score groups were estimated using the World Health Organisation functional class, right atrial pressure, cardiac index and mixed venous oxygen saturation, having significant difference (p=0.02) on survival (Figure 1), as expected.

The study participants are more likely to be women (68%) with age at diagnosis 51yrs, ±16yrs standard deviation (sd). The pulmonary hemodynamic characteristics of the study participants were: 1) Right Atrial Pressure, 9mm Hg, ±5sd; 2) Mean pulmonary arterial pressure, 53mm Hg, ±14sd; 3) Cardiac Index, 2L/min per m\textsuperscript{2}, ±0.6sd; 4) Cardiac Output, 4L/min, ±1.2sd; 5) Pulmonary Vascular Resistance, 12WU, ±5sd; and 6) Mixed venous oxygen saturation, 64%, ±8sd. We found no association between mortality and classes of area deprivation, for both the primary and adjusted model. As an example, adjusted hazard ratio (HR) was 0.63 (95% CI 0.18-2.16), p=0.458 for most deprived (quintile-5) areas compared to least deprived (quintile-1) areas. To examine this further, we investigated area deprivation as predictor to risk profiles, fitting multinomial regression models. We found an association between risk profiles and area deprivation, while adjusting for the same variables as above. Living within the more deprived areas (quintile-5, quintile-4, quintile-3) was associated with higher PAH risk score at baseline, compared to the least deprived areas (quintile-1), therefore increasing the likelihood of being diagnosed within the ESC/ERS high-risk clinical prediction category. Testing for the overall effect of deprivation to risk profiles, we found a statistically significant predictor effect (p=0.034, Wald-test). The relative risk ratio changing from least (quintile-1) to most (quintile-5) deprived area is 15.01 (95% CI 1.96-114.96), p=0.009, for being classed in high risk profile vs low risk profile. This was 14.59 (95% CI 2.22-95.9), p=0.005 and 9.75 (95% CI 1.42-67.06), p=0.021 for quintile-4, quintile-3, respectively. In other words, we found that the expected risk for being in high-risk class is higher for subjects who live in the most-deprived areas. The baseline risk class was also found to be a predictor of mortality in this survival analysis [adjusted HA 6.71 (95% CI 1.22-36.87), p=0.028], in line with literature \textsuperscript{3-5}.

The notion that deprivation is associated with increased mortality and morbidity for the most deprived compared with the most affluent, is confirmed by many studies and therefore has been enshrined in health studies, theories and policies\textsuperscript{6-9}. The main aspects of deprivation are income, employment and education that can be collected at area-level and individual level or, preferably, both. The choice for using composite index or its subdomains or individual-level deprivation, is driven by the research question and availability of deprivation indicators. Studies have faced numerous challenges in terms of using a composite area-level deprivation index. The data required are based on coverage of routinely collected data, which can vary between countries, using also a weighting score that depends on the priorities set by each country, making these indices not comparable. Usually, though, the highest weights are given to income, employment and educational deprivation and therefore it is possible the composite index is similar to indices that are based on any of these traditional deprivation markers. Still, we recommend not to assume that any differences would have no impact on the results, especially when using small datasets as the models can be too sensitive.

Even when such an index is used for the intended geographical area it was created for, the geographical distributions of sub-indices may have opposing directions, introducing error on the overall measure of deprivation. For instance, a high deprivation score should reflect both areas of low income and difficulty to access health care, with the latter often being measured as distance to primary health care centre. Patients who live near city centres, which tend to have higher income deprivation, may not have a long distance to access a primary care centre, while the opposite holds for wealthier populations that may live outside the city centre. Thus, the estimated composite deprivation can be compromised. Even the traditional indicators of income and education deprivation may vary substantially across areas\textsuperscript{10}. Any differences can be understood, by mapping the individual domains, which is important when considering how such data is used in analyses.
Composite IMD indices, including the Scottish IMD used by Pellino et al., have a health subdomain calculated based on standardised mortality ratio among other variables, so PAH mortality may be captured in some degree by this sub-domain. Therefore, ideally, the health sub-domain should not be included when deprivation is examined in relation to mortality. Finally, we would argue that even when prognosis is not associated with deprivation, this cannot directly lead to the interpretation that prognosis is not affected by access to care and referrals. Deprivation is linked to several parameters that affect health (i.e. diet, air quality) other than just equity on access to health services.

A notable feature of the UK NHS specialised commissioning structure for PAH is the equity of access to all licensed treatments to all patients, once they have been referred to the centres. A possible interpretation of our results and Pellino et al is therefore that deprivation acts as a barrier to referral but once in the specialised system, the equity of treatment availability diminishes the subsequent effect on mortality. We feel it cannot be ignored that unlike previous work that showed a significant effect of deprivation on mortality \[11\] both UK studies of similar sample sizes have failed to demonstrate an association with mortality and in health systems with more equal access to licensed treatment.

There are some limitations to this work. It is common for rare disease projects to analyse hundreds of cases, compared to thousands or millions in common diseases, for the same or similar research questions\[12, 13\], leading to the need to adopt refined datasets and analytical methods. The introduction of measurement error when using a deprivation index is likely to affect small datasets disproportionately and needs to be used with caution when conducting sensitivity analysis. Lastly, we are unable to quantify the effect of patients potentially not surviving to first admission to a tertiary PH care centre, and this drop out is theoretically more significant specifically because of the association we find with baseline risk stratification.

Overall, the result of Pellino and colleagues' study is an important piece in the PAH aetiology puzzle and the results of our study are in line with their lack of association between mortality and social deprivation; although we would caution that both studies are of modest size. At the same time, Pellino and colleagues' study found that PAH patients are more socially deprived than expected, based on Scottish citizenry as a whole. This alludes that deprivation status may have an association with PAH rather than it was a random finding. Our study adds further to the literature by demonstrating that higher area deprivation is associated with a worse risk profile at baseline, which in turn is a predictor of worse survival rates, suggesting that the issue of social deprivation and outcomes in PAH may be more nuanced. Examining both primary healthcare and hospital data in PAH could provide evidence on whether in deprived areas delays on PAH diagnosis are associated with the patient taking longer to seek help and the time required for tests related to the diagnosis.
Figure 1 Transplant-free survival in relation to risk profile, at the time of diagnosis (N=270).

References

2. Abel Gary, P.R., Barclay Matt, UK Deprivation Indices. 2016 [cited 2018; Available from: https://doi.org/10.5523/bris.1ef3q32gykb001v77c1fmy7x.